U.S. Markets close in 5 hrs 14 mins

Brooks Automation Announces Expansion of Life Science Systems Business With Acquisition of Celigo(R) Cell Cytometer Product Line

CHELMSFORD, Mass., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Brooks Automation, Inc. (Nasdaq:BRKS - News), a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy, today announced that it had completed the acquisition of the Celigo(R) Cell Cytometer product line from Cyntellect Inc., a privately held life sciences Company based in San Diego.


Introduced to the market in early 2010, Celigo has become one of the most rapidly adopted cell imaging systems based on its unique combination of high-throughput, ease-of-use, and affordability. The installed customer base for Celigo includes many of the top pharmaceutical, biotechnology, and academic institutions worldwide.

As part of the transaction, the majority of Cyntellect's employees who have supported Celigo since inception are being moved to Brooks' nearby facility in Poway, CA, providing for a seamless transition of the key engineering, manufacturing, and R&D capabilities, as well as the field based sales and support personnel.

Dr. Steve Schwartz, President and CEO of Brooks, stated, "The Celigo cellular imaging product line is an impressive addition to our family of stand-alone instrumentation products used by many of our automated sample management system life sciences customers. It joins a growing portfolio of high productivity automated solutions for the analysis, handling and testing of biological and compound samples prior to and following their storage in our automated sample management systems."

Dr. Schwartz continued, "The Celigo cell cytometer enables microplate-based high-throughput, high-content, brightfield and fluorescence cellular imaging and analysis, with minimal sample manipulation."

Saiid Zarrabian, President and CEO of Cyntellect, stated, "We are thrilled to have found a tremendous partner in Brooks to take Celigo to the next level. When combined with Brooks' world-class infrastructure, global commercial reach and worldwide customer support, Celigo will have the opportunity to penetrate markets that otherwise weren't accessible to Cyntellect. We are confident that Celigo's rapid early market penetration will be greatly accelerated by Brooks."

The purchase price was disclosed as up to approximately $9.2 million with settlement of part of the purchase price deferred for a six month period.

About Brooks Automation, Inc.

Brooks is a leading worldwide provider of automation, vacuum and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies and global service capabilities provide customers speed to market, and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, we have been a leading partner to the global semiconductor manufacturing market and through product development initiatives and strategic business acquisitions; we have expanded our reach to meet the needs of customers in the life sciences industry, analytical & research markets and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe and Asia. For more information, please visit www.brooks.com.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include statements regarding future adoption of new technologies and our ability to develop further our business. Factors that could cause results to differ from our expectations and other risks that we have identified are described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result we can provide no assurance that our future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertakes no obligation to update the information contained in this press release.